MVT 602

Drug Profile

MVT 602

Alternative Names: MVT-602; RVT-602; TAK-448

Latest Information Update: 02 Jun 2017

Price : $50

At a glance

  • Originator Millennium
  • Developer Millennium; Takeda; Takeda Oncology
  • Class Infertility therapies; Oligopeptides
  • Mechanism of Action KISS1R protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypogonadism
  • Discontinued Prostate cancer

Most Recent Events

  • 08 Jun 2017 Myovant Sciences plans a phase I trial for Female infertility (In volunteers) in the second half of 2017
  • 08 Jun 2017 Myovant Sciences plans a phase II proof-of-concept trial for Female infertility
  • 30 Mar 2017 Takeda terminates a phase II trial in Hypogonadism in United Kingdom because the study did not achieve the primary efficacy objective (NCT02369796)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top